GlassScriptPhysician profile
Jaclynn Campos
NPI 1346877586
$5,401.65
in general payments reported to CMS, 2019-2025
19 companies · $879 in 2025
The $879 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $524 · 2022: $1,656 · 2023: $1,514 · 2024: $829 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.28 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $821.68 | 2022-2025 | Pomalyst, Reblozyl, Breyanzi |
| Incyte Corporation | $670.88 | 2021-2025 | Niktimvo, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $390.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $381.04 | 2023-2025 | |
| Janssen Biotech, INC. | $377.12 | 2022-2024 | Tecvayli, Talvey |
| Amgen INC. | $315.51 | 2022-2024 | Blincyto |
| Novartis Pharmaceuticals Corporation | $304.57 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $300.35 | 2022 | |
| Genentech USA, INC. | $263.88 | 2023-2025 | Lunsumio, Columvi, Polivy |
| Jazz Pharmaceuticals INC. | $260.33 | 2022-2025 | |
| Seagen INC. | $205.81 | 2023 | Adcetris |
| Genentech, INC. | $196.85 | 2023 | Venclexta |
| Legend Biotech USA INC. | $188.54 | 2023-2025 | Carvykti |
| Daiichi Sankyo INC. | $123.97 | 2022 | |
| Astellas Pharma US INC | $122.55 | 2025 | Xospata |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $122.13 | 2024 | Clonoseq |
| Omeros Corporation | $122.01 | 2021 | |
| Celgene Corporation | $118.89 | 2021 | |
| Rigel Pharmaceuticals, INC. | $114.55 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclynn Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.